98%
921
2 minutes
20
Introduction: Cutaneous T-cell dyscrasia (CTCD) encompasses a heterogeneous group of T-cell infiltrates, often clonal and epitheliotropic. While the etiology remains unclear, certain medications, including statins, have been linked to cutaneous T-cell lymphocytic infiltrate development.
Case Description: A patient presented with a pruritic, scaly eruption on her palms and soles unresponsive to topical steroids for 1 month. Histopathological examination revealed compact orthokeratosis, mild lymphocytic infiltrate with focal exocytosis, and atypical lymphocytes. Immunophenotyping demonstrated a predominance of CD3+ T cells with a 1:1 CD4/CD8 ratio and reduced CD7 expression. The clinical presentation, histopathology, and immunophenotype supported a diagnosis of statin-induced CTCD.
Conclusion: Statin discontinuation led to complete symptom resolution, emphasizing the reversibility of drug-induced T-cell dyscrasia. This case highlights the importance of a detailed medication history as drug-induced T-cell dyscrasia, unlike classic CTCD with its characteristic lymphoid atypia, phenotypic abnormalities, and clonality leading to a refractory course, can be reversed by drug withdrawal.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11509488 | PMC |
http://dx.doi.org/10.1159/000541258 | DOI Listing |
Best Pract Res Clin Haematol
September 2025
Center for Early Detection and Interception of Blood Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. Electronic address:
Precursor plasma cell disorders include monoclonal gammopathy of undermined significance (MGUS) and smoldering multiple myeloma (SMM). These conditions carry a variable risk of progression to symptomatic myeloma and there are ongoing efforts to improve risk stratification to identify patients that are at highest risk of progression. Advanced imaging plays a crucial role in diagnosis and monitoring, and more sensitive tools to measure serum monoclonal proteins and circulating tumor cells are being developed.
View Article and Find Full Text PDFCurr Oncol
July 2025
Arthur Child Comprehensive Cancer Centre, Calgary, AB T2N 4N2, Canada.
Light-chain (AL) amyloidosis is a rare clonal plasma cell disorder that, if left untreated, carries a high risk of organ damage and mortality. Due to the rarity of the disease and the vulnerability of affected organ systems, treatment requires significant caution and nuance. As a plasma cell dyscrasia, AL amyloidosis treatment regimens are often adapted from those used for related disorders, particularly multiple myeloma.
View Article and Find Full Text PDFRheumatol Int
August 2025
Department of Pathology and Cytology, Clinical Hospital Center Rijeka, Rijeka, Croatia.
The association between autoimmune diseases and lymphoproliferative disorders is well established. It is also recognized that the skin and deep subcutaneous tissue can be affected by lymphocytic infiltrates in autoimmune diseases, a hallmark of lupus erythematosus profundus or lupus panniculitis (LP). To present an unusual lymphoproliferative disorder in a patient with undifferentiated connective tissue disease (UCTD).
View Article and Find Full Text PDFAm J Hematol
September 2025
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Front Immunol
May 2025
Department of Hematology, Mayo Clinic, Rochester, MN, United States.
Chimeric antigen receptor (CAR) cellular therapies have advanced outcomes in challenging hematologic malignancies like leukemia, lymphoma, and multiple myeloma. Plasma cell-directed CAR T-cell therapies have been particularly beneficial in multiple myeloma, suggesting that these agents may have a role in other challenging plasma cell disorders such as systemic AL amyloidosis and plasma cell leukemia. AL amyloidosis is a monoclonal plasma cell disorder resulting in the deposition of protein fibrils that compromise end-organ function.
View Article and Find Full Text PDF